173 related articles for article (PubMed ID: 22632603)
1. Organotypic systems in drug metabolism and toxicity: challenges and opportunities.
Dash A; Blackman BR; Wamhoff BR
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):999-1014. PubMed ID: 22632603
[TBL] [Abstract][Full Text] [Related]
2. Hepatocytes--the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo.
Gómez-Lechón MJ; Castell JV; Donato MT
Chem Biol Interact; 2007 May; 168(1):30-50. PubMed ID: 17134688
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system.
Darnell M; Ulvestad M; Ellis E; Weidolf L; Andersson TB
J Pharmacol Exp Ther; 2012 Oct; 343(1):134-44. PubMed ID: 22776955
[TBL] [Abstract][Full Text] [Related]
4. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model.
Chang R; Emami K; Wu H; Sun W
Biofabrication; 2010 Dec; 2(4):045004. PubMed ID: 21079286
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of drug metabolism, drug-drug interactions, and in vitro hepatotoxicity with cryopreserved human hepatocytes.
Li AP
Methods Mol Biol; 2010; 640():281-94. PubMed ID: 20645058
[TBL] [Abstract][Full Text] [Related]
6. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity.
Kostadinova R; Boess F; Applegate D; Suter L; Weiser T; Singer T; Naughton B; Roth A
Toxicol Appl Pharmacol; 2013 Apr; 268(1):1-16. PubMed ID: 23352505
[TBL] [Abstract][Full Text] [Related]
7. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity.
Astashkina A; Mann B; Grainger DW
Pharmacol Ther; 2012 Apr; 134(1):82-106. PubMed ID: 22252140
[TBL] [Abstract][Full Text] [Related]
8. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models.
Sukardi H; Chng HT; Chan EC; Gong Z; Lam SH
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):579-89. PubMed ID: 21345150
[TBL] [Abstract][Full Text] [Related]
9. The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.
Andersson TB; Kanebratt KP; Kenna JG
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):909-20. PubMed ID: 22568886
[TBL] [Abstract][Full Text] [Related]
10. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
[TBL] [Abstract][Full Text] [Related]
11. High-throughput human metabolism and toxicity analysis.
Lee MY; Dordick JS
Curr Opin Biotechnol; 2006 Dec; 17(6):619-27. PubMed ID: 17046235
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the latest in vitro tools for drug metabolism studies.
Costa A; Sarmento B; Seabra V
Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):103-19. PubMed ID: 24205859
[TBL] [Abstract][Full Text] [Related]
13. Human hepatocytes: isolation, cryopreservation and applications in drug development.
Li AP
Chem Biol Interact; 2007 May; 168(1):16-29. PubMed ID: 17270162
[TBL] [Abstract][Full Text] [Related]
14. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening.
Prot JM; Videau O; Brochot C; Legallais C; Bénech H; Leclerc E
Int J Pharm; 2011 Apr; 408(1-2):67-75. PubMed ID: 21295126
[TBL] [Abstract][Full Text] [Related]
15. In vivo zebrafish assays for analyzing drug toxicity.
Raldúa D; Piña B
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):685-97. PubMed ID: 24617455
[TBL] [Abstract][Full Text] [Related]
16. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
Tsaioun K; Jacewicz M
Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
[TBL] [Abstract][Full Text] [Related]
17. The early estimation of circulating drug metabolites in humans.
Luffer-Atlas D
Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
[TBL] [Abstract][Full Text] [Related]
18. Addressing the challenges of low clearance in drug research.
Di L; Obach RS
AAPS J; 2015 Mar; 17(2):352-7. PubMed ID: 25567366
[TBL] [Abstract][Full Text] [Related]
19. The multicellular tumor spheroid model for high-throughput cancer drug discovery.
LaBarbera DV; Reid BG; Yoo BH
Expert Opin Drug Discov; 2012 Sep; 7(9):819-30. PubMed ID: 22788761
[TBL] [Abstract][Full Text] [Related]
20. The role of body-on-a-chip devices in drug and toxicity studies.
Esch MB; King TL; Shuler ML
Annu Rev Biomed Eng; 2011 Aug; 13():55-72. PubMed ID: 21513459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
